PriceTargets.com logo

DBV Technologies - DBVT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 575.68%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.74 As of 11/30/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for DBVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DBV Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DBVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DBVT

Analyst Price Target is $5.00
▲ +575.68% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for DBV Technologies in the last 3 months. The average price target is $5.00, with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a 575.68% upside from the last price of $0.74.

This chart shows the closing price for DBVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in DBV Technologies. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
11/2/2023The Goldman Sachs GroupLower TargetSell ➝ Sell$1.30 ➝ $1.00Low
8/1/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$4.00Low
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
3/3/2023JMP SecuritiesReiterated RatingMarket Outperform$4.00Low
3/3/2023HC WainwrightReiterated RatingBuy$10.00Low
1/4/2023Societe GeneraleUpgradeHold ➝ BuyLow
12/16/2022The Goldman Sachs GroupDowngradeNeutral ➝ SellLow
8/4/2022Kepler Capital MarketsUpgradeHold ➝ Buy€6.00Low
6/8/2022JMP SecuritiesReiterated RatingBuy$5.00High
5/9/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$6.00 ➝ $1.50Low
5/3/2022HC WainwrightReiterated RatingBuy$10.00High
3/4/2022HC WainwrightReiterated RatingBuy$10.00Low
1/19/2022Societe GeneraleDowngradeBuy ➝ HoldHigh
12/22/2021UBS GroupDowngradeBuy ➝ NeutralLow
12/21/2021HC WainwrightLower TargetBuy$14.00 ➝ $10.00High
12/21/2021JMP SecuritiesLower TargetMarket Outperform$8.00 ➝ $5.00High
10/15/2021JMP SecuritiesReiterated RatingBuy$11.00High
9/14/2021Societe GeneraleUpgradeHold ➝ BuyHigh
5/4/2021Societe GeneraleUpgradeSell ➝ HoldMedium
5/3/2021Bryan, Garnier & CoUpgradeSell ➝ BuyLow
3/12/2021SVB LeerinkReiterated RatingOutperformMedium
1/22/2021Societe GeneraleDowngradeHold ➝ SellLow
1/18/2021The Goldman Sachs GroupBoost Target$4.00 ➝ $7.00N/A
1/15/2021CitigroupBoost Target$4.00 ➝ $8.00High
11/2/2020Societe GeneraleUpgradeSell ➝ HoldHigh
8/11/2020Jefferies Financial GroupReiterated RatingHold$2.50Medium
8/6/2020Societe GeneraleDowngradeBuy ➝ SellHigh
8/5/2020Morgan StanleyLower TargetEqual Weight$4.00 ➝ $2.00Low
8/5/2020CitigroupLower TargetBuy$10.00 ➝ $4.00High
8/5/2020HC WainwrightLower TargetBuy$25.00 ➝ $14.00High
8/4/2020Bryan, Garnier & CoDowngradeNeutral ➝ SellHigh
7/2/2020JMP SecuritiesInitiated CoverageBuy$10.00Low
6/26/2020Stifel NicolausReiterated RatingHoldHigh
4/6/2020CitigroupLower TargetBuy$14.00 ➝ $10.00Low
3/20/2020Kepler Capital MarketsDowngradeBuy ➝ HoldHigh
3/18/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralHigh
3/18/2020Morgan StanleyLower TargetEqual Weight$11.00 ➝ $4.00High
3/17/2020JMP SecuritiesLower Target$20.00 ➝ $10.00N/A
3/16/2020Stifel NicolausDowngradeBuy ➝ Hold$18.00 ➝ $6.00N/A
3/4/2020SVB LeerinkReiterated RatingOutperformHigh
3/4/2020Stifel NicolausReiterated RatingBuy$18.00High
1/8/2020Stifel NicolausUpgradeHold ➝ Buy$10.00 ➝ $18.00High
12/19/2019HC WainwrightReiterated RatingBuy$25.00High
12/16/2019CitigroupInitiated CoverageBuy$14.00Low
10/16/2019Oddo BhfUpgradeNeutral ➝ BuyLow
10/8/2019HC WainwrightReiterated RatingBuy$25.00High
6/17/2019The Goldman Sachs GroupInitiated CoverageBuy$14.00Low
3/6/2019Stifel NicolausReiterated RatingHold$10.00Low
3/6/2019JMP SecuritiesReiterated RatingBuy$20.00Low
12/20/2018SVB LeerinkReiterated RatingOutperformMedium
12/20/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$26.00 ➝ $10.00N/A
12/20/2018JMP SecuritiesLower TargetMarket Outperform$30.00 ➝ $20.00N/A
12/20/2018HC WainwrightLower TargetBuy$50.00 ➝ $25.00N/A
12/20/2018Bank of AmericaDowngradeBuy ➝ UnderperformN/A
12/20/2018Stifel NicolausDowngradeBuy ➝ Hold$11.00N/A
12/20/2018BarclaysDowngradeOverweight ➝ Equal Weight$30.00 ➝ $8.00N/A
12/20/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$5.25N/A
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2023
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

DBV Technologies logo
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Read More

Today's Range

Now: $0.74
Low: $0.71
High: $0.75

50 Day Range

MA: $1.06
Low: $0.74
High: $1.44

52 Week Range

Now: $0.74
Low: $0.65
High: $2.37

Volume

654,023 shs

Average Volume

159,499 shs

Market Capitalization

$142.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of DBV Technologies?

The following Wall Street sell-side analysts have issued stock ratings on DBV Technologies in the last year: HC Wainwright, JMP Securities, Societe Generale, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for DBVT.

What is the current price target for DBV Technologies?

3 Wall Street analysts have set twelve-month price targets for DBV Technologies in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 575.7%. HC Wainwright has the highest price target set, predicting DBVT will reach $10.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $1.00 for DBV Technologies in the next year.
View the latest price targets for DBVT.

What is the current consensus analyst rating for DBV Technologies?

DBV Technologies currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DBVT.

What other companies compete with DBV Technologies?

Other companies that are similar to DBV Technologies include Monte Rosa Therapeutics, Molecular Partners, Genfit, ERYTECH Pharma and Kodiak Sciences. Learn More about companies similar to DBV Technologies.

How do I contact DBV Technologies' investor relations team?

DBV Technologies' physical mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company's listed phone number is (315) 542-7878 and its investor relations email address is [email protected]. The official website for DBV Technologies is www.dbv-technologies.com. Learn More about contacing DBV Technologies investor relations.